UK Backs 14 Projects to Speed Up Adaptation in the Wild

The UK's Advanced Research and Invention Agency (Aria) has chosen 14 teams to share an initial £30m over the next two years. The selections were announced on 21 September 2026. The awards are the first part of a £54m programme called Accelerated Adaptation. The Guardian

The programme plans to use biotechnology to speed up evolution in wild species and help them cope with global warming and disease. Aria is a UK public body that funds high-risk, high-reward technology projects. Yannick Wurm directs the Accelerated Adaptation programme.

The 14 projects include vaccines for ash trees, gene-edited swallowtail butterflies and skin treatments for newts.

A team led by the University of Exeter will use Crispr-Cas9 gene editing, a method that cuts DNA at precise points to change traits, to increase resistance in swallowtail butterflies to insecticides used on farms. A Rothamsted Research project will edit genes in long-lived trees such as oaks so they reproduce in months rather than decades.

ARIA describes itself as a UK R&D funding agency built to unlock scientific and technological breakthroughs. ARIA It lists Resilient Climate and Ecosystems as one of its opportunity spaces, or priority areas. It places Accelerated Adaptation within that space.

On 21 September 2026, ARIA featured an Accelerated Adaptation entry inviting readers to meet the Creators funded in the programme. Its homepage links that entry to an official funded-projects page at /opportunity-spaces/resilient-climate-and-ecosystems/accelerated-adaptation/funded-projects. The funding process includes a Full proposals stage. The programme funds interdisciplinary teams, groups from different fields working together, to develop approaches to accelerate adaptation. ASU

The broader context here is a shift from conserving what exists toward helping species persist under pressure. Vaccinating trees, treating amphibian skin, editing insecticide resistance into butterflies and shortening the reproductive timeline of oaks each work on a different biological lever. One addresses pathogens. Another addresses chemical exposure. A third addresses generation time, which has long limited tree breeding and restoration.

In my view, the design choices to watch are containment, reversibility and handoff. Two-year grants can show whether a method works in the laboratory and in controlled trials. They cannot settle multi-year ecological questions. The test will be how teams track off-target genetic effects, how edited traits behave once insects disperse or pollen moves, and how tree vaccines or newt treatments reach scale without repeated human help. Funders can absorb technical failure. Ecosystems carry it differently.

Looking at what this means for practitioners, the near-term questions are practical. Who monitors edited populations after funding ends. What thresholds call for pause or withdrawal. How local land managers, farmers and conservation groups work through trade-offs when a trait that helps one species affects others. Aria has framed the work as high-risk, high-reward. The reward at issue is not a product launch but wild populations that last without continued support. Whether biotechnology can deliver that result, and under whose care, will shape the next phase more than the first awards.